To print: Select File and then Print from your browser's menu

Title: Duloxetine Improves Functioning and Quality of Life in Patients with Anxiety Disorder: Presented at ADAA

"Duloxetine Improves Functioning and Quality of Life in Patients with Anxiety Disorder: Presented at ADAA"

By Jill Stein ST. LOUIS, MO -- April 3, 2007 -- At least a third of patients with generalised anxiety disorder (GAD) improve from an impaired score to a normative score on functional and quality of life measures after 9 to 10 weeks of duloxetine treatment, researchers announced here at the 27[^th Annual Meeting of the Anxiety Disorders Association of America (ADAA).

Susan Ball, PhD, associate scientific communications consultant, Lilly Research Laboratories, Indianapolis, Indiana, United States, reported data from a pooled analysis of 3 randomised, double-blind, placebo-controlled trials of duloxetine treatment that enrolled a total of 1,163 adults with GAD.

Two studies had a 10-week flexible-dose 60 to 120 mg/day regimen, and 1 study had a 9- week fixed-dose 60 or 120 mg/day regimen. Inclusion and exclusion criteria were the same for the 3 studies.

At enrolment, 89% of subjects scored in the impaired range on the Sheehan Disability Scale (SDS) global functioning score. In addition, 95% were in the impaired range on the Quality of Life Enjoyment and Satisfaction Short Form (Q-LES-Q-SF), and 76% were in the impaired range on the European Qualify of Life 5 Dimensions (EQ-5D).

The rates of impaired scores on role functioning and diminished wellbeing are consistent with prior studies of GAD patients, Dr. Ball said in her presentation on March 31^st.

Using the criteria of improvement to community values, duloxetine-treated patients were more likely to achieve this outcome on each quality of life measure (P < .001 for all comparisons). In fact, after acute therapy for 9 to 10 weeks, about one third to one half of duloxetine-treated patients had improved from an impaired score on the different functional and quality of life measures, and these percentages amounted to twice the rates of improvement observed in placebo-treated patients.

The study also found that functional remission was associated with at least a 60% improvement in efficacy scores from baseline to endpoint, and a Hamilton Anxiety Scale endpoint score less than or equal to 10 captured larger percentages of patients who had functional remission than did a cut-off score of 7 or less, Dr. Ball said.

The study was sponsored by Lilly.

[Presentation title: Examining Quality of Life in Patients with Generalized Anxiety Disorder: Clinical Relevance and Response to Duloxetine in Treatment. Abstract P62]

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.